Neuromuscular Electrical Stimulation For The Treatment of Diabetic Neuropathy
Key facts
- Who runs it
- Imperial College London
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 65 people enrolled
- Started
- 22 Aug 2023
- Ended
- 30 Jun 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Revitive Medic Coach (Actegy Ltd)
- Sham Revitive Medic Coach (Actegy Ltd)
- Record updated
- 9 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Aged ≥18 (no upper limit)
- Diagnosis of type 1 or type 2 diabetes based on World Health Organisation (WHO) definition
- Diagnosis of diabetic neuropathy based on validated screening questionnaire Michigan Neuropathy Screening Instrument score of ≥4
- Access to internet at home to use the Revitive App (study smartphones will be provided)
Who cannot take part
- Implanted electronic, cardiac or defibrillator device
- Severe vascular disease requiring invasive intervention
- Being treated for, or have the symptoms of, an existing deep vein thrombosis (DVT)
- Lacks capacity to provide informed consent
- Pregnant
- Other cause of peripheral neuropathy
- Current foot ulceration
- Used a neuromuscular electrical stimulation (NMES) device within 1 year of randomisation
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Diabetic neuropathy (DN) is the most common complication of diabetes, affecting almost 50% of people with diabetes over the course of their lives. Symptoms vary from numbness to burning, aching and hypersensitivity in the lower limbs, indicative of sensory nerve loss. Motor neurons can also be affected, leading to muscle weakness and mobility issues, thus preventing patients from engaging in daily routines. Further sequelae include foot ulceration and Charcot neuroarthropathy, which are risk factors for lower limb amputation and mortality. In the United Kingdom, the annual costs of DN alone exceed £300 million, with further complications expected to cost an additional £1 billion. Currently, management strategies for DN focus on prevention and pain management. Neuromuscular electrical stimulation (NMES) is a novel nonpharmacological intervention for people with DN. NMES is the application of electrical impulses which are of sufficiency intensity to improve artificial contraction of the muscle tissue and may help with DN by improving nerve conductivity through direct stimulation of the nerves.
The 2 groups in the trial
- Control groupSham treatment, for comparison
Standard of Care + Sham Revitive Medic Coach (Sham Neuromuscular Electrical Stimulation Device) for 12 weeks
Treatment: Sham Revitive Medic Coach (Actegy Ltd)
- Intervention groupExisting treatment, for comparison
Standard of Care + Revitive Medic Coach (Neuromuscular Electrical Stimulation Device) for 12 weeks
Treatment: Revitive Medic Coach (Actegy Ltd)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Neuromuscular Electrical Stimulation For The Treatment Of Diabetic Neuropathy: A Multicentre, Double-blind, Pilot, Randomised, Sham-controlled Trial
- Record updated
- 9 April 2025